Paul H. Lange
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Paul H. Lange has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Alvin Y. Liu
Department of Urology, Institute for Stem Cells and Regenerative Medicine, University of Washington, Seattle, WA, USA
2 shared publications - Eva Corey
Department of Urology, University of Washington, Seattle, WA 98195, USA
2 shared publications - Peter S. Nelson
Human Biology Division, Fred Hutchinson Cancer Center, Seattle, USA
2 shared publications - Robert L. Vessella
Department of Urology, University of Washington, Seattle, WA 98195, USA
2 shared publications - Robert L. Vessella
Department of Veterans Affairs Medical Center, Seattle, WA, USA
2 shared publications - Bruce Montgomery
Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington, USA
1 shared publication
Latest Publications
- Open Access
- 16 February 2013
- Published by Springer Nature in BMC Molecular Biology
- Vol. 14 (1) , 1-11
Single cell transcriptomic analysis of prostate cancer cells
The ability to interrogate circulating tumor cells (CTC) and disseminated tumor cells (DTC) is restricted by the small number detected and isolated (typically <10). To determine if a commercially available technology could provide a transcriptomic profile of a single prostate cancer (PCa) cell, we clonally selected and cultured a single passage of cell cycle synchronized C4-2B PCa cells. Ten sets of single, 5-, or 10-cells were isolated using a micromanipulator under direct visualization with an inverted microscope. Additionally, two groups of 10 individual DTC, each isolated from bone marrow of 2 patients with metastatic PCa were obtained. RNA was amplified using the WT-Ovation™ One-Direct Amplification System. The amplified material was hybridized on a 44K Whole Human Gene Expression Microarray. A high stringency threshold, a mean Alexa Fluor® 3 signal intensity above 300, was used for gene detection. Relative expression levels were validated for select genes using real-time PCR (RT-qPCR). Using this approach, 22,410, 20,423, and 17,009 probes were positive on the arrays from 10-cell pools, 5-cell pools, and single-cells, respectively. The sensitivity and specificity of gene detection on the single-cell analyses were 0.739 and 0.972 respectively when compared to 10-cell pools, and 0.814 and 0.979 respectively when compared to 5-cell pools, demonstrating a low false positive rate. Among 10,000 randomly selected pairs of genes, the Pearson correlation coefficient was 0.875 between the single-cell and 5-cell pools and 0.783 between the single-cell and 10-cell pools. As expected, abundant transcripts in the 5- and 10-cell samples were detected by RT-qPCR in the single-cell isolates, while lower abundance messages were not. Using the same stringency, 16,039 probes were positive on the patient single-cell arrays. Cluster analysis showed that all 10 DTC grouped together within each patient. A transcriptomic profile can be reliably obtained from a single cell using commercially available technology. As expected, fewer amplified genes are detected from a single-cell sample than from pooled-cell samples, however this method can be used to reliably obtain a transcriptomic profile from DTC isolated from the bone marrow of patients with PCa.
- 16 February 2013
- Published by Springer Nature in BMC Molecular Biology
- Vol. 14 (1) , 1-11
Open AccessSingle cell transcriptomic analysis of prostate cancer cells
The ability to interrogate circulating tumor cells (CTC) and disseminated tumor cells (DTC) is restricted by the small number detected and isolated (typically <10). To determine if a commercially available technology could provide a transcriptomic profile of a single prostate cancer (PCa) cell, we clonally selected and cultured a single passage of cell cycle synchronized C4-2B PCa cells. Ten sets of single, 5-, or 10-cells were isolated using a micromanipulator under direct visualization with an inverted microscope. Additionally, two groups of 10 individual DTC, each isolated from bone marrow of 2 patients with metastatic PCa were obtained. RNA was amplified using the WT-Ovation™ One-Direct Amplification System. The amplified material was hybridized on a 44K Whole Human Gene Expression Microarray. A high stringency threshold, a mean Alexa Fluor® 3 signal intensity above 300, was used for gene detection. Relative expression levels were validated for select genes using real-time PCR (RT-qPCR). Using this approach, 22,410, 20,423, and 17,009 probes were positive on the arrays from 10-cell pools, 5-cell pools, and single-cells, respectively. The sensitivity and specificity of gene detection on the single-cell analyses were 0.739 and 0.972 respectively when compared to 10-cell pools, and 0.814 and 0.979 respectively when compared to 5-cell pools, demonstrating a low false positive rate. Among 10,000 randomly selected pairs of genes, the Pearson correlation coefficient was 0.875 between the single-cell and 5-cell pools and 0.783 between the single-cell and 10-cell pools. As expected, abundant transcripts in the 5- and 10-cell samples were detected by RT-qPCR in the single-cell isolates, while lower abundance messages were not. Using the same stringency, 16,039 probes were positive on the patient single-cell arrays. Cluster analysis showed that all 10 DTC grouped together within each patient. A transcriptomic profile can be reliably obtained from a single cell using commercially available technology. As expected, fewer amplified genes are detected from a single-cell sample than from pooled-cell samples, however this method can be used to reliably obtain a transcriptomic profile from DTC isolated from the bone marrow of patients with PCa.
- 1 August 2010
- Published by Elsevier in European Urology
- Vol. 58 (2) , 311-312
Re: Phase 1 Trial of High-Dose Exogenous Testosterone in Patients with Castration-Resistant Metastatic Prostate Cancer
- 1 August 2010
- Published by Elsevier in European Urology
- Vol. 58 (2) , 311-312
Re: Phase 1 Trial of High-Dose Exogenous Testosterone in Patients with Castration-Resistant Metastatic Prostate Cancer
- 1 February 2009
- Published by Elsevier in European Urology
- Vol. 55 (2) , 524-525
Re: Adjuvant Radiotherapy for Patients with Locally Advanced Prostate Cancer—A New Standard?
- 1 February 2009
- Published by Elsevier in European Urology
- Vol. 55 (2) , 524-525
Re: Adjuvant Radiotherapy for Patients with Locally Advanced Prostate Cancer—A New Standard?
- 1 January 2007
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 25 (1) , 2-10
Genitourinary oncology and its surgeon scientists: Triumphant past, but does it have a future?
- 1 January 2007
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 25 (1) , 2-10
Genitourinary oncology and its surgeon scientists: Triumphant past, but does it have a future?
- 1 January 2001
- Published by Springer Nature
- Vol. 53, 217-242
Experimental Models and Methods in Antibody Targeting of Renal Cell Carcinoma
Metastatic renal cell carcinoma (RCC) is incurable and there are few treatment options that assure even a short prolongation in survival. It is the most common malignancy of the adult kidney and accounts for approximately 12,000 deaths per year (1). Due to a lack of diagnostic markers for early detection and the infrequency of notable symptoms early in the disease process, about one third of patients present with known metastatic disease. However, the staging of RCC is an inaccurate science and in 40% of those patients where a nephrectomy is the treatment choice for presumed organ-confined disease, metastases become evident within about 1 yr (2). For reasons that are poorly understood, metastatic RCC has remained relatively resistant to chemotherapy, biological response modifiers and cellular immunotherapy—although, glimpses of encouragement have appeared in numerous studies. These are discussed in great depth throughout the accompanying chapters.
- 1 January 2001
- Published by Springer Nature
- Vol. 53, 217-242
Experimental Models and Methods in Antibody Targeting of Renal Cell Carcinoma
Metastatic renal cell carcinoma (RCC) is incurable and there are few treatment options that assure even a short prolongation in survival. It is the most common malignancy of the adult kidney and accounts for approximately 12,000 deaths per year (1). Due to a lack of diagnostic markers for early detection and the infrequency of notable symptoms early in the disease process, about one third of patients present with known metastatic disease. However, the staging of RCC is an inaccurate science and in 40% of those patients where a nephrectomy is the treatment choice for presumed organ-confined disease, metastases become evident within about 1 yr (2). For reasons that are poorly understood, metastatic RCC has remained relatively resistant to chemotherapy, biological response modifiers and cellular immunotherapy—although, glimpses of encouragement have appeared in numerous studies. These are discussed in great depth throughout the accompanying chapters.
- 1 December 1998
- Published by Springer Nature in Cancer and Metastasis Reviews
- Vol. 17 (4) , 331-336
Mechanisms, Hypotheses and Questions Regarding Prostate Cancer Micrometastases to Bone
The morbidity and mortality associated with prostate cancer can almost universally be attributed to the consequences of metastases to the bone. While clinically there have been descriptive reports of...
- 1 December 1998
- Published by Springer Nature in Cancer and Metastasis Reviews
- Vol. 17 (4) , 331-336
Mechanisms, Hypotheses and Questions Regarding Prostate Cancer Micrometastases to Bone
The morbidity and mortality associated with prostate cancer can almost universally be attributed to the consequences of metastases to the bone. While clinically there have been descriptive reports of...
- 15 February 1997
- Published by Wiley in The Prostate
- Vol. 30 (3) , 145-153
Identification of differentially expressed prostate genes: Increased expression of transcription factor ETS-2 in prostate cancer
- 15 February 1997
- Published by Wiley in The Prostate
- Vol. 30 (3) , 145-153
Identification of differentially expressed prostate genes: Increased expression of transcription factor ETS-2 in prostate cancer
- Open Access
- 3 January 1996
- Published by Wiley in International Journal of Cancer
- Vol. 65 (1) , 85-89
Prostatic cell lineage markers: Emergence of BCL2 cells of human prostate cancer xenograft LuCaP 23 following castration
- 3 January 1996
- Published by Wiley in International Journal of Cancer
- Vol. 65 (1) , 85-89
Open AccessProstatic cell lineage markers: Emergence of BCL2 cells of human prostate cancer xenograft LuCaP 23 following castration